Par Pharmaceutical Companies, Inc.™ develops, manufactures, markets and distributes high-quality pharmaceuticals through two divisions:
, our generic drug division, and
, our proprietary products division. We combine the energy and innovation of a new venture with the fully integrated resources of a leading, diversified pharmaceutical company.
Founded as a generics products company in 1978. Today includes two divisions:
- Employs more than 600 professionals in offices in Woodcliff Lake, New Jersey (Corporate Headquarters), Spring Valley, New Yor...
|08/06/14||Par Pharmaceutical Announces Quarterly Conference Call|
|Woodcliff Lake, N.J., August 6, 2014 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, August 13, 2014 at 10:00 a.m. EDT to review its results of operations for the second quarter ended June 30, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission. Par will file its financial statements for the quarter ended June 30, 2014 with th... |
|07/09/14||Par Pharmaceutical Begins Shipment of Fluphenazine Decanoate Injection, USP|
|Woodcliff Lake, NJ, July 9, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fluphenazine decanoate injection, USP 25 mg/mL. Fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine decanoate ... |
|06/10/14||Strativa Pharmaceuticals Announces FDA Approval of Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device|
|One Spray per Device, Without the Need for Priming, Provides Greater Ease of Use
Woodcliff Lake, NJ, June 10, 2014 – Strativa Pharmaceuticals, the branded division of Par Pharmaceutical Companies, Inc., today announced that the U.S. Food and Drug Administration has approved Nascobal® Nasal Spray in a single-use device. Nascobal® is a prescription vitamin B12 supplement administered as one spray, one nostril, once a week. Each single-use device delivers one spray of 500 mcg of cyanocob... |
|05/28/14||Par Pharmaceutical Statement on Brevital® Sodium|
|Woodcliff Lake, NJ, May 27, 2014 – Par Pharmaceutical Companies, Inc. today issued the following statement in response to inquiries it has received regarding the potential use of Brevital® Sodium (methohexital sodium for injection, USP) by the State of Indiana Department of Correction as part of a three-drug lethal injection protocol:
Brevital® is a medically important anesthetic that physicians and hospital pharmacies have relied upon for more than 50 years. The state of Indiana’s ... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.